Department of Life Science, National Taiwan Normal University, Taipei, Taiwan, ROC; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; Department of Pediatrics, National Yang-Ming University School of Medicine, Faculty of Medicine, Taipei, Taiwan, ROC.
Department of Life Science, National Taiwan Normal University, Taipei, Taiwan, ROC.
J Chin Med Assoc. 2018 Jun;81(6):541-547. doi: 10.1016/j.jcma.2017.11.012. Epub 2018 Feb 17.
The incidence of hepatoblastoma is not well known in Taiwan. The goal of this study was to investigate the incidence rates of hepatoblastoma by age and sex.
The data of patients with hepatoblastoma diagnosed from 1995 to 2012 were obtained from the population-based Taiwan Cancer Registry. Incidence rates of hepatoblastoma according to sex and age were analyzed. This study employed the published methods of International Agency for Research on Cancer to calculate the age-standardized incidence rates (ASIRs), standard errors, 95% confidence intervals (CIs), and standardized incidence rate ratios (SIRRs).
In total, 211 patients were diagnosed with hepatoblastoma during the 18-year study period. The ASIR was 0.76 per million person-years. Hepatoblastoma was predominantly diagnosed in children (n = 184, 87.2%). By contrast, adolescents/adults (n = 10, 4.7%) and elderly people (n = 17, 8.1%) were rarely affected. The incidence peaked at ages 0-4 years with corresponding ASIR of 7.3 per million person-years. A significant male predilection was only found in children and elderly people, with male-to-female SIRRs of 1.23 and 1.89, respectively. During 1995-2012, the overall incidence of hepatoblastoma significantly increased only in children (annual percent change: 7.4%, 95% CI 3.9%-11.1%, p < 0.05) and specifically in boys (annual percent change: 6.5%, 95% CI 1.9%-11.2%, p < 0.05).
Only 27 patients aged ≥ 15 years with hepatoblastoma were identified in this study, the existence of adult hepatoblastoma still requires novel molecular tools to elucidate. The association between the upward trend of hepatoblastoma incidence in boys and increased survival of prematurity in Taiwan warrants further investigations.
在台湾，肝母细胞瘤的发病率尚不清楚。本研究的目的是调查肝母细胞瘤的发病率随年龄和性别的变化。
从基于人群的台湾癌症登记处获取 1995 年至 2012 年期间诊断为肝母细胞瘤的患者数据。按性别和年龄分析肝母细胞瘤的发病率。本研究采用国际癌症研究机构公布的方法计算年龄标准化发病率（ASIR）、标准误差、95%置信区间（CI）和标准化发病比（SIRR）。
在 18 年的研究期间，共有 211 例患者被诊断为肝母细胞瘤。ASIR 为 0.76/百万人年。肝母细胞瘤主要发生在儿童（n=184，87.2%），青少年/成年人（n=10，4.7%）和老年人（n=17，8.1%）罕见。发病率在 0-4 岁年龄组达到高峰，对应的 ASIR 为 7.3/百万人年。仅在儿童和老年人中发现男性明显偏多，男女性别比 SIRR 分别为 1.23 和 1.89。1995-2012 年，肝母细胞瘤的总体发病率仅在儿童中显著增加（年变化率：7.4%，95%CI 3.9%-11.1%，p<0.05），特别是男孩（年变化率：6.5%，95%CI 1.9%-11.2%，p<0.05）。
本研究仅发现 27 例年龄≥15 岁的肝母细胞瘤患者，成人肝母细胞瘤仍需要新的分子工具来阐明。台湾男孩肝母细胞瘤发病率上升与早产儿存活率增加之间的关联需要进一步调查。
